Low serum paraoxonase: A risk factor for atherosclerotic disease?

Chemico-Biological Interactions

Volumn 119-120, Issue , 1999, Pages 389-397

  Mackness, Michael I ^a   Durrington, Paul N ^a   Ayub, Aamir ^a   Mackness, Bharti ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Coronary heart disease; High density lipoprotein; Lipid peroxides; Low density lipoprotein; Oxidation; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CONFERENCE PAPER; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HUMAN; LIPID METABOLISM; LIPID OXIDATION; NONHUMAN; RISK FACTOR;

ANIMALS; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; ESTERASES; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS;

MAMMALIA;

EID: 0033039311     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00050-2     Document Type: Conference Paper

References (33)

1. Mackness M.I. Possible medical significance of human serum paraoxonase. Reiner E., Aldridge W.N., Hoskin F.C.G. Enzymes Hydrolysing Organophosporus Compounds. 1989;202-213 Ellis Horwood, Chichester.
2. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154.
3. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1989;915-924.
4. Mackness M.I., Durrington P.N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
5. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135.
6. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fault K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase-Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
7. Watson A.D., Navab M., Hama S.Y., Sevanian A., Prescott S.M., Stafforini D.M., McIntyre T.M., La Du B.N., Fogelman A.M., Berliner J.A. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J. Clin. Invest. 95:1995;774-782.
8. Klimov A.N., Nikiforova A.A., Pleskov V.M., Kuz'min A.A., Kalashnikova N.N., Antipova T.O. The protective action of high-density lipoproteins, their subfractions and lecithin-cholesterol acyltransferase in the peroxide modification of low-density lipoproteins. Biokkimiya. 54:1989;118-123.
9. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow G.C., Carelinez C.J., Castellani L.W., Brennan M.-L., La Du B.N., Lusis A.J., Fogelman A.M. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:1997;2005-2019.
10. Castellani L.W., Navab M., Van Lenten B.J., Hedrick C.C., Hama S.Y., Goto A.M., Fogelman A.M., Lusis A.J. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100:1997;464-474.
11. Shih D.M., Gu L., Hama S., Xia Y.-R., Navab M., Fogelman A.M., Lusis A.J. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1996;1630-1639.
12. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:1993;598-608.
13. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
14. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:1996;334-336.
15. Blatter-Garin M.-C., James R.W., Dussoix P., Blanché H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J. Clin. Invest. 99:1997;62-66.
16. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 112:1997;265-268.
17. Primo-Parma S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33:1996;498-509.
18. Hegele R.A., Connelly P.W., Scherer S.W., Hanley A.J.G., Harris S.B., Tsui L.-C., Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;3373-3377.
19. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15:1995;89-95.
20. Hegele R.A., Brunt J.H., Connelly P.W. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler. Thromb. Vasc. Biol. 15:1995;861-871.
21. Sanghera D.K., Saha N., Kamboh M.I. The codon 55 polymorphism of the paraoxonase 1 gene is not associated with risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
22. Mackness M.I., Arrol S., Mackness B., Durrington P.N. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet. 349:1997;851-852.
23. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423:1998;57-60.
24. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1233-1238.
25. Mackness M.I., Mackness B., Arrol S., Wood G., Bhatnagar D., Durrington P.N. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 416:1997;377-380.
26. Ruiz J., Blanché H., James R.W., Blatter-Garin M.-C., Vaise C., Charpeutier G., Cohen N., Morabia A., Possa P., Froguel P. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
27. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
28. Herrmann S.M., Blanc H., Poirier O., Arveiter D., Luc G., Evans A., Marques-Vidal P., Bard J.M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126:1996;299-304.
29. Antikainen M., Murtomäki S., Syvänne M., Pahlman R., Tahvanainen E., Jauhiainen M., Frick M.H., Ehnholm C. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
30. Suehiro T., Nakauchi Y., Yamamoto M., Arii K., Itoh H., Hamashige N., Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57:1996;69-73.
31. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073.
32. 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
33. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y.A. A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:1997;3565-3569.